Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: Merck's Follow-On Insulin Edges Closer To Market; Braeburn Submits Another Buprenorphine Depot

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.


Related Content

Keeping Track: An RMAT, Two QIDPs, And Some Bad News Too
Merck's Lantus Copy Lusduna Poised For US Market Pending Litigation
Insulin Market Competition: Payers Watching FDA 'Transition' Policy
Keeping Track: Oncology Announcements, Priority Review Vouchers Continue To Pile Up
Keeping Track: US FDA Approves Siliq, Accepts Mylan/Biocon Pegfilgrastim Biosimilar
Otonomy To Challenge Multi-Dose Ear Drops With Otiprio Expansion Plans
Keeping Track: A Good Week For Biologics And Probuphine, Less So For Eteplirsen And ZS-9
Sanofi Settlement With Lilly Paves The Way For Biosimilar Lantus


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts